Clinical trials: BIA
Parkinson's Disease
Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
The objectives as stated in the study protocol were as follows: To investigate the safety and tolerability of three multiple dose regimens of BIA 3-202 (50 mg twice a day, 100 mg twice a day and 200 mg twice a day in healthy…
- Trial name
- NCT02763800
- Testing
- BIA 3-202
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Cardiovascular Diseases
Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058
The purpose of the study is to determine the mass balance recovery in expired air, urine and faeces after a single oral dose of 400 mg 14C-labeled BIA 5-1058; to provide plasma, urine and faecal samples for metabolite profiling…
- Trial name
- NCT04069130
- Testing
- 400 mg of BIA 5-1058
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD)
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg…
- Trial name
- NCT02170376
- Testing
- BIA 9-1067, Entacapone, Levodopa/carbidopa
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients with moderate chronic hepatic impairment and in matched healthy subjects.
- Trial name
- NCT02101190
- Testing
- BIA 9-1067
- Where
- 3 sites in France, Russia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on the pharmacokinetics (PK) of sildenafil. To assess the effect of sildenafil on the PK of BIA 5-1058.
- Trial name
- NCT04994860
- Testing
- BIA 5-1058, Sildenafil
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Sepsis
Clinical Protocol Validation to Identify Prognostic Markers for Critical Care Pediatric Patients
The purpose of this study is to monitor the respiratory, metabolic and nutritional status of critically ill pediatric patients undergoing mechanical ventilation and to correlate the clinical and physiopathological findings with…
- Trial name
- PCL07 (NCT00792883)
- Where
- Brazil
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Parkinson Disease
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.
- Trial name
- NCT01532128
- Testing
- rasagiline, BIA 9-1067
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Chronic Kidney Disease
Body Fluid Dynamics in Hemodialysis Patients, an Estimation of Dry Weight
The purpose of this study is to learn how the amount of fluid in the body of a hemodialysis patient affects him or her. Body hydration is the amount of fluid in the human body and known to be related to blood pressure.
- Trial name
- NCT02325908
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Renal Research Institute
Pulmonary Arterial Hypertension
Effect of Food on BIA 5-1058
The aim of this study is to investigate the effect of food on the pharmacokinetic (PK) profile of BIA 5-1058 after a single dose in healthy subjects.
- Trial name
- NCT04991155
- Testing
- BIA 5-1058
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Relapsing Remitting Multiple Sclerosis (RRMS), Malnutrition or Risk of Malnutrition
The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis
This prospective observational study aims to determine the prevalence of malnutrition in patients with relapsing-remitting multiple sclerosis and to evaluate its association with disability.
- Trial name
- NCT07497126
- Where
- Turkey (Türkiye)
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Parkinson Disease
Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects
the purpose of the study was to the compare pharmacokinetic profile of BIA 6-512 in healthy elderly subjects versus healthy young subjects after single and repeated oral administration of 200 mg BIA 6-512.
- Trial name
- NCT03095105
- Testing
- 200 mg BIA 6-512
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Anesthesia
The Neuromuscular Effect of Rocuronium in Patient
Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of…
- Trial name
- NCT02657187
- Testing
- Inbody, Rocuronium
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Go Eun Bae
Diet Habits, Athlete
Legume-Enriched Mediterranean Diet and Cellular Hydration in Competitive Swimmers
This study investigates whether increasing legume consumption within a Mediterranean diet framework improves cellular hydration, autonomic regulation, and functional performance in competitive swimmers.
- Trial name
- LEGUMES-SWIM (NCT07315529)
- Testing
- Legume-enriched Mediterranean diet
- Where
- Italy
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- San Raffaele Telematic University
Body Composition
Validation of the New HAG-B19 Scale for Measuring Lean and Fat Body Masse
Body composition measurement is an important tool for assessing the physical condition of sick or healthy people, as well as for monitoring changes in body composition and physical performance during diet and/or training.
- Trial name
- HAG-BIA (NCT04504799)
- Testing
- Body composition measurement with HAG-BIA scale
- Where
- Switzerland
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Prof. Claude Pichard
Parkinson's Disease (PD)
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a…
- Trial name
- NCT02169414
- Testing
- BIA 9-1067 5 mg, BIA 9-1067 25 mg, levodopa/carbidopa 100/25
- Where
- France
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202
The purpose of this study is to investigate the safety and tolerability of single oral rising doses of BIA 3-202 up to 800 mg (proposed doses 10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg) in groups of 9 healthy male…
- Trial name
- NCT02763787
- Testing
- BIA 3-202
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension, Chronic Heart Failure
Pharmacokinetics of BIA 5-453 and Its Metabolites
The purpose of this study was to assess the effects of age on the pharmacokinetic (PK) profile of BIA 5-453 and its metabolites.
- Trial name
- NCT03090724
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects
The purpose of this study is to determine the effects of age on the pharmacokinetic (PK) profile of BIA 9-1067 and its metabolites.
- Trial name
- NCT02092168
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Cardiovascular Disease+Pulmonary Disease, Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
This is a single centre, double-blind, randomised, placebo-controlled, parallel staggered group study of BIA 5-1058 in 11 different cohorts of 15 healthy subjects.
- Trial name
- NCT03708146
- Testing
- BIA 5-1058
- Where
- United Kingdom
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls. The trial consisted of a screening visit, a treatment phase and a follow-up visit.
- Trial name
- NCT02281526
- Testing
- BIA 2-093
- Where
- South Africa
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.